All In Biotech

NDA 210868 · Pfizer

Lorbrena

Lorlatinib · Oral · Kinase Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 2, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

59

3 Phase 3, 16 recruiting

FAERS reports

7,455

6,225 serious, 2,070 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 26, 2026.

LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )

Mechanism: Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors. In mice subcutaneously implanted with tumors harboring EML4 fusions with either ALK variant 1 or ALK mutations, including the G1202R and I1171T mutations detected in tumors at the time of disease progression on ALK inhibitors, administration of...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 3, 2021 Supplement 4 · Efficacy · priority review OrphanLabelLetter
  • Nov 2, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • LORBRENA · LORLATINIB 25MG · TABLET, ORAL · Prescription
  • LORBRENA · LORLATINIB 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lorlatinib" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,486
  • neoplasm progression620
  • off label use457
  • hallucination447
  • weight increased433
  • blood cholesterol increased381
  • dyspnoea293
  • malignant neoplasm progression285
  • oedema280
  • fatigue273
  • oedema peripheral270
  • peripheral swelling229

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
20176
201856
2019552
2020508
2021595
2022692
2023918
20241,225
20251,565
20261,336

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jun 15, 2026

    Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03). Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lorbrena (Lorlatinib)

2024 spending

$117M

Beneficiaries

868

5,896 claims

Per beneficiary

$134,486

$485.61 per unit

View as table
YearSpending
2020$31,446,261
2021$42,609,600
2022$61,934,706
2023$75,625,415
2024$116,734,265

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 72 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.